Cargando…
P473: CRISPR/CAS9 GENE EDITING CLARIFIES THE ROLE OF CD33 SNP RS12459419 IN GEMTUZUMAB OZOGAMICIN-MEDIATED CYTOTOXICITY
Autores principales: | Oya, Shuki, Ozawa, Hidetoshi, Nakamura, Takayuki, Maehiro, Yoshimi, Takaki, Yusuke, Fukuyama, Yoshinobu, Yamasaki, Yoshitaka, Yamaguchi, Maki, Aoyama, Kazutoshi, Mouri, Fumihiko, Nagafuji, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429479/ http://dx.doi.org/10.1097/01.HS9.0000968800.53072.ea |
Ejemplares similares
-
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
por: Castaño-Bonilla, Tamara, et al.
Publicado: (2022) -
Gemtuzumab Ozogamicin: Back Again
por: Selby, Chris, et al.
Publicado: (2019) -
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
por: Teich, Katrin, et al.
Publicado: (2021) -
Gemtuzumab ozogamicin: Various toxicities: 2 case reports
Publicado: (2017) -
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)